ME03417B - Jedinjenje pladienolid piridina i postupci primjene - Google Patents
Jedinjenje pladienolid piridina i postupci primjeneInfo
- Publication number
- ME03417B ME03417B MEP-2019-81A MEP201981A ME03417B ME 03417 B ME03417 B ME 03417B ME P201981 A MEP201981 A ME P201981A ME 03417 B ME03417 B ME 03417B
- Authority
- ME
- Montenegro
- Prior art keywords
- processes
- pyridine compounds
- pladienolide pyridine
- pladienolide
- compounds
- Prior art date
Links
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical class C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Diaphragms For Electromechanical Transducers (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461993423P | 2014-05-15 | 2014-05-15 | |
| PCT/US2015/030464 WO2015175594A1 (en) | 2014-05-15 | 2015-05-13 | Pladienolide pyridine compounds and methods of use |
| EP15727125.5A EP3143016B1 (en) | 2014-05-15 | 2015-05-13 | Pladienolide pyridine compounds and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME03417B true ME03417B (me) | 2020-01-20 |
Family
ID=53284528
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2019-81A ME03417B (me) | 2014-05-15 | 2015-05-13 | Jedinjenje pladienolid piridina i postupci primjene |
Country Status (36)
| Country | Link |
|---|---|
| US (1) | US9481669B2 (me) |
| EP (2) | EP3514154B1 (me) |
| JP (1) | JP6067943B1 (me) |
| KR (2) | KR101710318B1 (me) |
| CN (1) | CN107074827B (me) |
| AR (1) | AR100431A1 (me) |
| AU (1) | AU2015259237B2 (me) |
| BR (1) | BR112016026638B1 (me) |
| CA (1) | CA2947754C (me) |
| CL (1) | CL2016002835A1 (me) |
| CY (1) | CY1121550T1 (me) |
| DK (1) | DK3143016T3 (me) |
| ES (1) | ES2712401T3 (me) |
| HR (1) | HRP20190432T1 (me) |
| HU (1) | HUE041838T2 (me) |
| IL (1) | IL248529B (me) |
| JO (1) | JO3668B1 (me) |
| LT (1) | LT3143016T (me) |
| MA (1) | MA39915B1 (me) |
| ME (1) | ME03417B (me) |
| MX (2) | MX373324B (me) |
| MY (1) | MY195081A (me) |
| PE (1) | PE20170384A1 (me) |
| PH (1) | PH12016502249B1 (me) |
| PL (1) | PL3143016T3 (me) |
| PT (1) | PT3143016T (me) |
| RS (1) | RS58400B1 (me) |
| RU (1) | RU2707730C2 (me) |
| SG (1) | SG11201609693XA (me) |
| SI (1) | SI3143016T1 (me) |
| SM (1) | SMT201900158T1 (me) |
| TR (1) | TR201902328T4 (me) |
| TW (1) | TWI634115B (me) |
| UA (1) | UA119458C2 (me) |
| WO (1) | WO2015175594A1 (me) |
| ZA (1) | ZA201607354B (me) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2887201T3 (es) | 2015-09-01 | 2021-12-22 | Eisai R&D Man Co Ltd | Variantes de empalme asociadas con mutantes neomórficos de SF3B1 |
| MX379655B (es) | 2015-11-18 | 2025-03-11 | Eisai R&D Man Co Ltd | Una forma en estado solido de compuestos de pladienolida piridina y metodos de uso. |
| AU2018235940A1 (en) | 2017-03-15 | 2019-10-17 | Eisai R&D Management Co., Ltd. | Spliceosome mutations and uses thereof |
| KR20200083532A (ko) | 2017-10-31 | 2020-07-08 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 적어도 1종의 스플라이세오솜 조정제, 및 bcl2 억제제, bcl2/bclxl 억제제 및 bclxl 억제제로부터 선택된 적어도 1종의 억제제를 포함하는 조합물 및 사용 방법 |
| TWI878153B (zh) * | 2018-04-09 | 2025-03-21 | 日商衛材R&D企管股份有限公司 | 特定普拉二烯內酯化合物及其使用方法 |
| CN117285502A (zh) * | 2018-04-12 | 2023-12-26 | 卫材R&D管理有限公司 | 作为用于治疗癌症的剪接体靶向剂的普拉二烯内酯衍生物 |
| US11998544B2 (en) * | 2018-06-01 | 2024-06-04 | Eisai R&D Management Co., Ltd. | Methods of using splicing modulators |
| US12172986B2 (en) | 2018-06-01 | 2024-12-24 | Eisai R&D Management Co., Ltd | Splicing modulator antibody-drug conjugates and methods of use |
| IL262658A (en) * | 2018-10-28 | 2020-04-30 | Memorial Sloan Kettering Cancer Center | Prevention of age related clonal hematopoiesis and diseases associated therewith |
| AU2021284401A1 (en) * | 2020-06-05 | 2023-01-05 | Eisai R&D Management Co., Ltd. | Anti-BCMA antibody-drug conjugates and methods of use |
| TW202233187A (zh) | 2020-11-04 | 2022-09-01 | 日商衛材R&D企管股份有限公司 | 骨髓發育不良症候群（ｍｄｓ）之生物標記物及其使用方法 |
| WO2022263702A1 (es) * | 2021-06-18 | 2022-12-22 | Universidad de Córdoba | Compuesto para el tratamiento del glioblastoma |
| CN113876771B (zh) * | 2021-11-12 | 2022-09-23 | 中国医学科学院基础医学研究所 | 一种靶向pabpc1的小分子药物及其在慢性髓系白血病中的应用 |
| WO2023131866A1 (en) | 2022-01-05 | 2023-07-13 | Eisai R&D Management Co., Ltd. | Biomarkers for myelodysplastic syndrome (mds) and methods of using the same |
| US20260062404A1 (en) | 2022-11-07 | 2026-03-05 | Eisai R&D Management Co., Ltd. | Method for producing macrolide compound |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI312681B (en) * | 2001-02-01 | 2009-08-01 | Novel physiologically active substance | |
| TWI334866B (en) | 2002-05-29 | 2010-12-21 | Mercian Corp | Novel physiologically active substances |
| WO2004011661A1 (ja) | 2002-07-31 | 2004-02-05 | Mercian Corporation | 新規生理活性物質 |
| EP1541570A4 (en) | 2002-07-31 | 2008-05-21 | Mercian Corp | NEW PHYSIOLOGICALLY EFFECTIVE SUBSTANCE |
| AU2003285012A1 (en) | 2002-10-24 | 2004-05-13 | Sepracor, Inc. | Compositions comprising zopiclone derivatives and methods of making and using the same |
| NZ540103A (en) | 2002-11-29 | 2007-05-31 | Mercian Corp | Process for producing macrolide compound |
| KR20060110865A (ko) | 2003-11-27 | 2006-10-25 | 에자이 가부시키가이샤 | 매크로라이드계 화합물의 수산화에 관여하는 ｄｎａ |
| ES2382987T3 (es) | 2003-11-28 | 2012-06-15 | Kanagawa Academy Of Science And Technology | Método de detección de cáncer de hígado, diagnóstico de cáncer de hígado y curación del cáncer |
| WO2006003706A1 (ja) | 2004-07-02 | 2006-01-12 | Plus One Techno & Co., Ltd. | 組み合わせ計量技術 |
| JP4599357B2 (ja) | 2004-07-20 | 2010-12-15 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | プラジエノライドの生合成に関与するポリペプチドをコードするｄｎａ |
| TW200716744A (en) * | 2005-05-26 | 2007-05-01 | Eisai R&D Man Co Ltd | Genetically modified microorganism and process for production of macrolide compound using the microorganism |
| WO2007043621A1 (ja) | 2005-10-13 | 2007-04-19 | Eisai R & D Management Co., Ltd. | プラジエノライド ｂ及びプラジエノライド ｄの全合成方法 |
| JPWO2008111464A1 (ja) * | 2007-03-05 | 2010-06-24 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | スプライシング異常を指標とする抗ガン剤の作用検定方法 |
| US20080312317A1 (en) | 2007-04-12 | 2008-12-18 | Eisai R&D Management Co., Ltd. | 12 membered-ring macrolactam derivatives |
-
2015
- 2015-05-13 AU AU2015259237A patent/AU2015259237B2/en active Active
- 2015-05-13 HR HRP20190432TT patent/HRP20190432T1/hr unknown
- 2015-05-13 SG SG11201609693XA patent/SG11201609693XA/en unknown
- 2015-05-13 EP EP18210019.8A patent/EP3514154B1/en active Active
- 2015-05-13 US US14/710,687 patent/US9481669B2/en active Active
- 2015-05-13 LT LTEP15727125.5T patent/LT3143016T/lt unknown
- 2015-05-13 MX MX2016014997A patent/MX373324B/es active IP Right Grant
- 2015-05-13 RU RU2016148887A patent/RU2707730C2/ru active
- 2015-05-13 PE PE2016002233A patent/PE20170384A1/es unknown
- 2015-05-13 CN CN201580025344.0A patent/CN107074827B/zh active Active
- 2015-05-13 DK DK15727125.5T patent/DK3143016T3/en active
- 2015-05-13 BR BR112016026638-2A patent/BR112016026638B1/pt active IP Right Grant
- 2015-05-13 ME MEP-2019-81A patent/ME03417B/me unknown
- 2015-05-13 UA UAA201612731A patent/UA119458C2/uk unknown
- 2015-05-13 TR TR2019/02328T patent/TR201902328T4/tr unknown
- 2015-05-13 MY MYPI2016001944A patent/MY195081A/en unknown
- 2015-05-13 PH PH1/2016/502249A patent/PH12016502249B1/en unknown
- 2015-05-13 RS RS20190233A patent/RS58400B1/sr unknown
- 2015-05-13 AR ARP150101485A patent/AR100431A1/es active IP Right Grant
- 2015-05-13 ES ES15727125T patent/ES2712401T3/es active Active
- 2015-05-13 MA MA39915A patent/MA39915B1/fr unknown
- 2015-05-13 MX MX2020004476A patent/MX388580B/es unknown
- 2015-05-13 KR KR1020167016648A patent/KR101710318B1/ko active Active
- 2015-05-13 HU HUE15727125A patent/HUE041838T2/hu unknown
- 2015-05-13 JO JOP/2015/0113A patent/JO3668B1/ar active
- 2015-05-13 CA CA2947754A patent/CA2947754C/en active Active
- 2015-05-13 SI SI201530641T patent/SI3143016T1/sl unknown
- 2015-05-13 PL PL15727125T patent/PL3143016T3/pl unknown
- 2015-05-13 KR KR1020177004442A patent/KR102146726B1/ko active Active
- 2015-05-13 SM SM20190158T patent/SMT201900158T1/it unknown
- 2015-05-13 EP EP15727125.5A patent/EP3143016B1/en active Active
- 2015-05-13 PT PT15727125T patent/PT3143016T/pt unknown
- 2015-05-13 TW TW104115293A patent/TWI634115B/zh active
- 2015-05-13 WO PCT/US2015/030464 patent/WO2015175594A1/en not_active Ceased
- 2015-05-13 JP JP2016526218A patent/JP6067943B1/ja active Active
-
2016
- 2016-10-25 ZA ZA2016/07354A patent/ZA201607354B/en unknown
- 2016-10-26 IL IL24852916A patent/IL248529B/en active IP Right Grant
- 2016-11-08 CL CL2016002835A patent/CL2016002835A1/es unknown
-
2019
- 2019-02-22 CY CY20191100228T patent/CY1121550T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA39915A (fr) | Composés de pladiénolide pyridine et leurs procédés d'utilisation | |
| MA43827A (fr) | Composés di-nucléotides cycliques et leurs procédés d'utilisation | |
| EP3504213A4 (en) | AMINO-PYRROLOPYRIMIDINONE COMPOUNDS AND METHOD FOR USE THEREOF | |
| EP3429635A4 (en) | ANTI-CRISPR COMPOUNDS AND METHOD OF USE | |
| EP3380101A4 (en) | EIF4-A-INHIBITING COMPOUNDS AND METHODS THEREFOR | |
| EP3359168A4 (en) | THERAPEUTIC COMPOUNDS AND METHOD | |
| MA49861A (fr) | Composés de benzoxazépine oxazolidinone et leurs procédés d'utilisation | |
| MA49858A (fr) | Composés, compositions et procédés | |
| PL3558197T3 (pl) | Wyroby chłonne zawierające laminaty zawierające elastomery wiązkowe | |
| EP3676297A4 (en) | COMPOUNDS, COMPOSITIONS, AND PROCEDURES | |
| MA43389A (fr) | Anticorps anti-ox40 et leurs procédés d'utilisation | |
| EP2968440A4 (en) | CYTOTOXIC AND ANTIMITOTIC COMPOUNDS AND METHOD FOR USE THEREOF | |
| EP3337486A4 (en) | DEUTERIZED CONNECTIONS AND USES THEREOF | |
| MA53145A (fr) | Agents de liaison cd123 et leurs utilisations | |
| EP3387023A4 (en) | METHOD FOR HYDROCARBON RECOVERY | |
| EP3319610A4 (en) | OXYSTEROLS AND METHOD OF USE THEREOF | |
| PL3247791T3 (pl) | Uniwersalne komórki nkt | |
| EP3319612A4 (en) | OXYSTEROLS AND METHOD OF USE THEREOF | |
| MA41296A (fr) | Procédés de transdifférenciation et procédés d'utilisation de ceux-ci | |
| DK3341303T3 (da) | Blisterpakning | |
| EP3377060A4 (en) | PYRAZOL COMPOUNDS AND METHOD FOR THE PRODUCTION AND USE THEREOF | |
| MA49560A (fr) | Composés cétoniques bicycliques et leurs procédés d'utilisation | |
| EP3303436A4 (en) | HYDROFLUOROLEFINES AND METHOD OF USE THEREOF | |
| DK3286260T3 (da) | Polyolefinrør | |
| EP3350196A4 (en) | CARBON COMPOUNDS AND METHOD FOR USE THEREOF |